Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CX3CR1 | P49238 | 20/20 | 1.00 |
| ▸ | CXCR2 | P25025 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31199186 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL20455391 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL18312509 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL214469 | 0.90 | CXCR2 (0.82) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL20465740 | 0.90 | CX3CR1 (0.82) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL9106210 | 0.89 | CX3CR1 (0.80) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL31199209 | 0.89 | CX3CR1 (0.80) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL9905774 | 0.89 | CX3CR1 (0.80) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL1588357 | 0.89 | CX3CR1 (0.80) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL215568 | 0.89 | CX3CR1 (0.80) | CX3CR1CXCR2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440992-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | claimed |
| US-7947693-B2 | 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | claimed |
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | claimed |
| EP-1869056-B1 | NOVEL 5-SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | EP | claimed |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | ACTURUM REAL ESTATE AB (SE) | 2008-09-04 | — | — | US | claimed |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-9856260-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-9440992-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8435993-B2 | Methods of inhibiting metastasis from cancer | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
| US-8088780-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| US-7947693-B2 | 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-1869056-B1 | NOVEL 5-SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | EP | disclosed |
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | ACTURUM REAL ESTATE AB (SE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | CX3CR1 1/4885CXCR2 7/4885ADORA1 368/4885 |
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | CX3CR1, CCR2, CXCR3 | CX3CR1 1/4885CXCR2 6/4885ADORA1 60/4885 |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | CX3CR1, CCL2, CCR5 | CX3CR1 1/4885CXCR2 7/4885ADORA1 368/4885 |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | CX3CR1, CCR2, CXCR3 | CX3CR1 1/4885CXCR2 11/4885ADORA1 69/4885 |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | CX3CR1, CXCR3, CCR5 | CX3CR1 1/4885CXCR2 7/4885ADORA1 336/4885 |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | CX3CR1 1/4885CXCR2 7/4885ADORA1 368/4885 |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | CX3CR1 1/4885CXCR2 7/4885ADORA1 368/4885 |
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | CX3CR1, CCR2, CCR5 | CX3CR1 1/4885CXCR2 5/4885ADORA1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.